FIELD: biotechnology.
SUBSTANCE: disclosed is an antibody or a binding fragment thereof, which specifically bind to a glucose carrier protein 4 (GLUT4). Invention also relates to compositions and methods for delivering a payload into cells or tissues which express GLUT4. Compositions contain said antibody or its binding fragment conjugated with a therapeutic payload. Payload contains a nucleic acid which codes a functional dystrophin protein or a functional fragment thereof. Compositions according to the invention are applicable for methods of treating a disease or condition in a subject with a genetic mutation in a gene coding a dystrophin protein.
EFFECT: invention provides non-viral vector platforms which can specifically deliver a therapeutic payload to muscle cells without payload size limitations.
27 cl, 25 dwg, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND METHODS OF ACTIVATING INTEGRINS | 2020 |
|
RU2836262C1 |
| ANTI-IL31 ANTIBODIES FOR USE IN VETERINARY SCIENCE | 2020 |
|
RU2835543C1 |
| FUSION PROTEIN COMPRISING IL-12 AND ANTI-FAP ANTIBODY, AND USE THEREOF | 2021 |
|
RU2831612C1 |
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| FUSED PROTEIN CONSTRUCTS FOR COMPLEMENT-RELATED DISEASE | 2019 |
|
RU2824402C2 |
| CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY AND USE THEREOF | 2020 |
|
RU2819228C2 |
| ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN, AND USE THEREOF | 2020 |
|
RU2825304C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2015 |
|
RU2743464C2 |
| CD47-ANTIGEN-BINDING UNIT AND ITS USE | 2018 |
|
RU2780859C2 |
